相关实验视频
Updated: Jan 7, 2026

05:17
Intravenous Injections in Neonatal Mice
Published on: November 11, 2014
60.8K
新生儿患者的万科米辛:系统性审查,并呼吁标准化剂量和监测实践
Cesar Helbel1, Camila Brusarosco Ferreira2, Camila Ferreira Amaral Previato1
1Graduate Program in Health Sciences, State University of Maringá , City: Maringá, 87020-900, PR, Brazil.
European journal of clinical pharmacology
|December 22, 2025
概括
新生儿重症监护室 (NICU) 的万科米辛剂量缺乏标准化,阻碍了最佳治疗. 进一步的研究对于新生儿安全有效的万科米辛方案至关重要.
科学领域:
- 新生儿药理学 新生儿药理学
- 传染性疾病 传染性疾病
- 临床药房 临床药房
背景情况:
- 范科米辛对于治疗新生儿严重的格拉姆阳性感染至关重要.
- 新生儿重症监护室 (NICU) 目前的剂量和治疗药物监测 (TDM) 实践不一致.
- 对新生儿的最佳万科米辛方案的证据是零碎的.
研究的目的:
- 在NICU新生儿中系统地审查万科米辛剂量,TDM,疗效和毒性.
- 为此群体确定最有效和最安全的万科米辛疗法.
- 巩固证据,以改善新生儿万科米辛的管理.
主要方法:
- 按照PRISMA指南进行系统审查.
- 搜索了六个主要的数据库,寻找观察性队列和随机临床试验.
- 提取了有关剂量,TDM目标,疗效和毒性的数据.
主要成果:
- 包括32项在剂量 (10-61毫克/公斤/天) 和TDM目标 (5-30毫克/升) 中具有显著异质性的研究.
- 有限的临床疗效数据 (3项研究) 和可变的毒性率 (1.1%-14%).
- 方法的变化阻碍了跨研究的比较.
结论:
- 在新生儿中缺乏标准化的万科米辛剂量和TDM实践.
- 定义最佳的治疗方案是具有挑战性的,因为不一致的方法.
- 需要进行高质量的研究,以确定对新生儿的安全和有效的万科米辛策略.
更多相关视频
相关概念视频
Drug Dosing: Infants and Children
226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
Pharmacokinetics in Pediatric Patients: Drug Excretion
188
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
188
Drug Dosage Regimen: Overview
4.3K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.3K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
204
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
204
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165

